Pliant Therapeutics Inc (PLRX): Price-to-Sales Ratio

Corporate company logo of Pliant Therapeutics (PLRX)

This chart on GURU.Markets reflects the price-to-sales ratio for Pliant Therapeutics (PLRX) through the lens of ESG standards and bioethics. Business growth remains independent of market cycles, relying solely on scientific breakthroughs, while inhibitor patents ensure high margins. The value of 3012.70 corresponds to the current metric, helping to identify emotional overheating of the stock or a prolonged decline in demand in a timely manner.

PLRX: pliantrx.com P/S Multiple 07/04/2022 - 08/08/2024

Metric breakdowns and analytics for Pliant Therapeutics (PLRX)

- share price and consensus valuation forecast:
Price Performance Chart pliantrx.com|PLRX - Price Target Chart
- stock exchange capitalization data:
Market Valuation Pliant Rx|PLRX - Enterprise Value
- balance sheet net asset value indicators:
Accounting Value of a Share Pliant Therapeutics|PLRX - Book Capitalization|Market Capitalization to Book Value Ratio pliantrx.com|PLRX - Aggregate Company Assets
- debt obligations and liquidity statistics:
All Debt to Shareholders' Equity Ratio Pliant Therapeutics|PLRX - Long-Term Debt to Equity|Short-Term Debt to Equity Ratio pliantrx.com|PLRX - Company Aggregate Debts|Debts to Book Capitalization Pliant Rx|PLRX - Company Long-Term Debt|Current Liabilities Pliant Therapeutics|Quick Liquidity pliantrx.com
- earnings and valuation multiples information:
PLRX - Net Profit|Company Profit Forecast Pliant Therapeutics|PLRX - P/E Multiple|Forward P/E Multiple pliantrx.com|PLRX - Price/Earnings to Growth Ratio|Enterprise Value to Operating Income Before Depreciation Pliant Rx|PLRX - Operating profit before deduction of amortization|Earnings per share for the last four quarters Pliant Therapeutics|PLRX - Net earnings per share for the last 12 months|Year-over-year earnings per one share growth for the last 12 months pliantrx.com|PLRX - Net earnings per share growth this year|Projected earnings per share increase next year Pliant Therapeutics
- issuer revenue and sales details:
PLRX - Revenue and Sales Volume|Company Future Revenue pliantrx.com|PLRX - P/S Multiple|Market Cap to Future Revenue Ratio Pliant Rx
General company analysis:PLRX Pliant Therapeutics Inc
Finished products of Pliant Therapeutics, Inc.

Pliant Therapeutics (PLRX) focuses on developing anti-fibrotic drugs and currently has no commercial products. The P/S multiple compares the business's market value to its annual revenue, measuring the premium for future success. By analyzing P/S fluctuations, an investor can see to what extent current expectations for clinical stages precede actual cash flow. The indicator's trend reflects shifting market sentiment regarding the issuer's R&D potential.

Competitors of Pliant Therapeutics

VRTX (vrtx.com) - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Alnylam ALNY|INSM (Insmed Inc.) - Price-to-Sales Ratio|United Therapeutics Corp. - P/S Multiple|Market Capitalization-to-Revenue Ratio BMRN (BioMarin Corp)|BBIO: P/S Multiple|BGM Group (BGM) - P/S Multiple|Price-to-Revenue Ratio Cogent Biosciences, Inc.|XERS: Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Keros Pharma (KROS)|Market Cap to Revenue Arcturus Corp ARCT|P/S Multiple ETON (Eton Pharmaceuticals)|P/S Multiple kamada.com KMDA|FULC - Price-to-Revenue Ratio|Price-to-Sales Ratio ABEO|mereobiopharma.com (MREO) - Price-to-Revenue Ratio|PLX (Protalix BioTherapeutics, Inc) - Price-to-Revenue Ratio|APLT (Applied Therapeutics) - P/S Multiple|aileronrx.com (RNTX) - Price-to-Revenue Coefficient|P/S Multiple GELS|P/S Multiple aytubio.com (AYTU)|Price-to-Revenue Ratio Chemomab Therapeutics Ltd. CMMB|SRXH: Market Cap to Revenue Ratio|PLRZ: Market Cap to Revenue|Aeterna Zentaris - Market Cap to Sales Volume|CYTH (Cyclo Therapeutics, Inc.) - Market Cap to Revenue|Inozyme Pharma - Market Capitalization-to-Revenue Ratio|Market Cap to Revenue RPHM|CSCI (COSCIENS Bio) - Market Cap to Sales Volume